 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phase
II Randomized Study of Rituximab and Alemtuzumab in Elderly Patients With
Progressive Chronic Lymphocytic Leukemia (No Drugs Provided)
ECOG 1908 (MBMC Contact: Henry Robinson
314-996-5865)
Click
For Consent
***
Phase III Randomized Study of Lenalidomide With Versus Without Epoetin Alfa
in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes and
Symptomatic Anemia
ECOG 2905
(MBMC Contact: Henry Robinson
314-996-5865)
Click
For Consent ***
● Diagnostic Study of Cytogenetics in Patients
With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic
Syndromes, or Multiple Myeloma - (This is a companion for
previously untreated Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia,
or Myelodysplastic Syndromes CALGB Treatment Studies)
CALGB 8461 (MBMC Contact: Henry Robinson 314-996-5865)
Click
For Consent
● Study to Collect and Store Specimens From
Patients With Previously Untreated Acute or Chronic Leukemia or
Myelodysplastic Syndromes - (This is a companion
for
Acute Leukemia, ChronicLeukemia, and Myelodysplastic Syndromes CALGB Treatment Studies)
CALGB 9665
(MBMC Contact: Henry Robinson 314-996-5865)
Click
For Consent
Leukemia and MDS Trials in St. Louis, MO***Available through CTSU
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|